Menu

Pursuing excellence in healthcare

We are pursuing excellence in healthcare by offering best-in-class medical devices and services. We firmly believe in personalized healthcare and it is our vision to provide the best therapeutic solutions tailored to the needs of the individual patient.

About us
210521_Toraymyxin-EAA-homepage_653x337px

Sepsis and septic shock

TORAYMYXIN®

State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with high mortality and a significant economic burden on the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000-fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin® – Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function, and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™ – Endotoxin Activity Assay – is the only FDA-approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.

chronic-kidney-disease-653x337

Chronic kidney disease

TORAY PMMA FILTRYZER

A personalized therapy based on the individual needs of each patient

Hemofeel_Web_EN_653x337px

Acute kidney injury

HEMOFEELTM

HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on

260508_SMART2026_653x337px
Events

SMART MEETING 2026 – MILANO

We will once again participate in the 37th edition of SMART Meeting Anesthesia Resuscitation Intensive Care, taking place from May 27 to 29, 2026, at Allianz MiCo, Milan.
As a partner of the congress, we will support two scientific sessions focused on extracorporeal organ support and endotoxic septic shock, with international experts discussing some of the most relevant challenges in intensive care medicine. We will also be present throughout the congress at our exhibition stand, where visitors can meet our team and learn more about our technologies and clinical solutions for critical care.

260417_Focus-On_TIGRIS_REV_653x337px
Clinical research

TIGRIS TRIAL RESULTS PUBLISHED

The TIGRIS trial results have been published in The Lancet Respiratory Medicine. In patients with endotoxic septic shock, Polymyxin B Hemoadsorption is associated with a high probability of lower mortality at 28 and 90 days. The Tigris trial shows a clinically meaningful signal of reduced mortality with polymyxin B in patients with ESS, alongside an acceptable safety profile.

260506_Focus-On_Certificati_EN_653x337px
Certifications

ESTOR OBTAINS ISO 13485 CERTIFICATION

ESTOR has obtained ISO 13485 certification, the international reference standard for quality management systems in the medical device sector. This achievement is a concrete recognition of the company’s ongoing commitment to safety, regulatory compliance, and the high performance of its products, further confirming its position as a reliable and innovative partner in the medical field.